790 related articles for article (PubMed ID: 1727926)
1. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
2. In transit metastases of malignant melanoma treated by high dose rTNF alpha in combination with interferon-gamma and melphalan in isolation perfusion.
Liénard D; Lejeune FJ; Ewalenko P
World J Surg; 1992; 16(2):234-40. PubMed ID: 1561804
[TBL] [Abstract][Full Text] [Related]
3. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
[TBL] [Abstract][Full Text] [Related]
4. Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
J Infus Chemother; 1995; 5(2):73-81. PubMed ID: 8521239
[TBL] [Abstract][Full Text] [Related]
5. Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
Eggermont AM; Schraffordt Koops H; Klausner JM; Liénard D; Kroon BB; Schlag PM; Ben-Ari G; Lejeune FJ
Semin Oncol; 1997 Oct; 24(5):547-55. PubMed ID: 9344321
[TBL] [Abstract][Full Text] [Related]
6. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
[TBL] [Abstract][Full Text] [Related]
7. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study.
Liénard D; Eggermont AM; Schraffordt Koops H; Kroon BB; Rosenkaimer F; Autier P; Lejeune FJ
Melanoma Res; 1994 Mar; 4 Suppl 1():21-6. PubMed ID: 8038591
[TBL] [Abstract][Full Text] [Related]
8. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan.
Santinami M; Deraco M; Azzarelli A; Cascinelli F; Chiti A; Costagli V; Inglese MG; Manzi R; Quagliolo V; Rebuffoni G; Santoro N; Vaglini M
Tumori; 1996; 82(6):579-84. PubMed ID: 9061068
[TBL] [Abstract][Full Text] [Related]
9. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
10. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
[TBL] [Abstract][Full Text] [Related]
11. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
13. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
[TBL] [Abstract][Full Text] [Related]
15. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
[TBL] [Abstract][Full Text] [Related]
16. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
[TBL] [Abstract][Full Text] [Related]
17. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs.
Eggimann P; Chioléro R; Chassot PG; Lienard D; Gerain J; Lejeune F
Chest; 1995 Apr; 107(4):1074-82. PubMed ID: 7705119
[TBL] [Abstract][Full Text] [Related]
18. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
19. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.
Thom AK; Alexander HR; Andrich MP; Barker WC; Rosenberg SA; Fraker DL
J Clin Oncol; 1995 Jan; 13(1):264-73. PubMed ID: 7799030
[TBL] [Abstract][Full Text] [Related]
20. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
